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Introduction
Of the gynecologic malignancies, ovarian cancer has
the highest mortality rate. It often eludes the clinician
because of the lack of early symptoms and signs,
presenting at a late clinical stage in more than 80%
of patients; ovarian cancer is associated with a low
5-year survival of 35% in this population [1–5]. In
contrast, the 5-year survival for patients with stage I
ovarian cancer exceeds 90% and most patients are
cured by surgery alone [3–5]. Therefore, increasing the
number of women diagnosed with stage I disease should
have a direct effect on the mortality and economics of
this cancer.
The identification of cancer biomarkers provides
the possibility for early detection, better monitoring of
tumor progression, and even targeting therapy [1–7].
Traditional strategies for cancer biomarker identification
used tumor cells to immunize animals and screen for
antibodies that could efficiently recognize the antigen
[8]. This approach is limited by its high cost and labor
intensity but has produced the best-known marker
approved for ovarian cancer monitoring, CA125 [8].
More recently, tumor mRNA has been compared with
normal tissue mRNA to identify upregulated genes in
cancer tissue, using cDNA microarrays to identify a
SUMMARY
Objective: Proteomic profiling of plasma or serum is a technique to identify new biomarkers in disease. The
objective of this study was to identify new plasma biomarkers in ovarian cancer patients using mass spectrometry
protein profiling and artificial intelligence.
Methods: A total of 65 plasma samples obtained from women with ovarian cancer (n = 35) and age-matched
disease-free controls (n = 30) were applied to anion exchange protein chips for protein profiling by surface-
enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS).
Results: SELDI-TOF MS was highly reproducible in detecting ovarian tumor-specific protein profiles. One protein
peak (relative molecular mass, Mr, 11,537 Da) was identified in plasma from women with ovarian cancer but
not in controls. Two peaks, Mr 5,147 and 8,780 Da, were present in the plasma of controls but not of women
with ovarian cancer. After a training analysis, classification analysis generated by univariant or linear combination
split was performed to reach a discriminant protein signature pattern. After cross validation, a sensitivity of
84% and specificity of 89% for all studied cases and controls was reached.
Conclusion: This study clearly demonstrates that the combined technology of SELDI-TOF MS and artificial
intelligence is effective in distinguishing protein expression between normal and ovarian cancer plasma. The
identified protein peaks may be candidate proteins for early detection of ovarian cancer or evaluation of
therapeutic response. [Taiwanese J Obstet Gynecol 2006;45(1):26–32]
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variety of markers, including prostasin, osteopontin,
and He4 [9–11]. A limitation of the cDNA microarray
approach is that transcriptional differences in the tumor
do not completely reflect the protein observed peripher-
ally, because many protein–protein interactions and
post-translational modifications may change the protein
patterns found in blood.
Recently, a protein chip coupled with surface-
enhanced laser desorption/ionization time-of-flight
mass spectrometry (SELDI-TOF MS) has been developed
to facilitate protein profiling of complex biological mix-
tures, with high efficacy of discovery of cancer protein
markers in serum or plasma [12–14]. The objective of
this study was to determine whether SELDI-TOF MS
profiling of plasma proteins coupled with an artificial
intelligence data analysis algorithm could effectively
discriminate between normal controls and patients
with malignant ovarian cancer. Using a standardized
training set, we demonstrated that our SELDI protein
profiling approach could accurately discriminate
between plasma from patients with ovarian cancer and
that from women who do not have ovarian disease. Our
results form the basis for initiating further evaluation
and validation to assess the potential of this SELDI
proteomic classification system for the early detection
and diagnosis of ovarian cancer, a clinically important
lethal cancer.
Methods
Patients and specimens
All patient-related biological specimens were collected
and archived under protocols approved by the in-
stitutional review board of the Tri-Service General
Hospital, Taiwan, as described previously [15]. Informed
consent was obtained from each patient and control
subject. Plasma was collected preoperatively from
women requiring surgery for ovarian tumors. Healthy,
age-matched (< 3 years) controls were enrolled from
women attending the clinic for routine Pap screening.
The current analysis was based on plasma specimens
from 30 patients who had surgically and histologically
proven ovarian cancers (15 serous cystadenocarcino-
ma, 5 mucinous cystadenocarcinoma, 2 endometrioid
adenocarcinoma, 2 malignant Brenner tumors, 3 poorly
differentiated adenocarcinoma, and 3 secondary meta-
static tumors). There were 35 plasma specimens from
age-matched controls, who had no history of gynecologic
tumors and had a normal pelvic examination and/or
pelvic sonography. Plasma was prepared from EGTA-
anticoagulated peripheral blood, aliquoted, and stored
at –80$C, generally within 4 hours after collection.
Materials
Strong anion exchange (SAX) protein chips and other
SELDI-related materials were obtained from Cipher-
gen Biosystems (Fremont, CA, USA). NP-40 and
phosphate-buffered saline (PBS) came from Invitrogen
(Carlsbad, CA, USA) and trifluoroacetic acid was from
Pierce (Rockford, IL, USA). All other general chemicals
were purchased from Sigma (St. Louis, MO, USA).
Matrix preparation and SELDI calibration
Calibration of the SELDI system was carried out before
each analytical session. Sinapinic acid matrix was pre-
pared freshly on the day of use by sequential addition
of 125 +L of acetonitrile and 125 +L of 1% trifluoroace-
tic acid to an aliquot of matrix. This was vortexed and
stored in the dark. Before use, the matrix was micro-
fuged at 13,000 rpm for 1 minute. For calibration pur-
poses, an H4 chip spot was loaded with 2 +L of matrix
containing all-in-one protein standard. The mix included
cytochrome C (12.2 kDa), myoglobin (17.0 kDa), gly-
ceraldehyde-3-phosphate dehydrogenase (35.7 kDa),
albumin (66.4 kDa), and `-galactosidase (116.4 kDa).
After air drying, the mixture was analyzed on the SELDI
system using high mass acquisition of 40 kDa, optimum
mass range of 3–20 kDa, laser intensity of 210, sensitivity
of 10, and 50 collecting transients across the spot
surface. Calibration was performed using single- and
double-charged peaks for each calibrant.
SAX2 protein chip analysis
Diluted plasma samples (1:10) were processed on
SAX2 chips according to the manufacturer’s protocols
(Ciphergen Biosystems). Briefly, the array spots were
preactivated with binding buffer (1 +L PBS/0.1% Triton
X-100, pH 7.5) at room temperature for 15 minutes
in a humidifying chamber. Each diluted sample (3 +L)
was spotted onto preactivated SAX2 chips and in-
cubated in a humidity chamber for 30 minutes at room
temperature. The chips were washed twice with bind-
ing buffer and once with high-performance liquid
chromatography-grade water, and then air-dried. The
chips were then sequentially treated with saturated
sinapinic acid (with 50% acetonitrile and 0.5% tri-
fluoroacetic acid) and analyzed with the Ciphergen
ProteinChip Reader, PBSII (Ciphergen Biosystems).
SELDI data analysis
Spectra were analyzed with Ciphergen ProteinChip
software (version 3.1) and normalized using total ion
current. Peak clustering in the 2–30-kDa range was per-
formed using Biomarker Wizard Software (Ciphergen
Biosystems) at settings that provide a 5% minimum
peak threshold, 0.2% mass window, and 2–3% signal/
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noise determination. Intensity values for each peak
were then averaged for each duplicate sample pair
analyzed and input into BioMarker Patterns software
(Ciphergen Biosystems) for classification tree analysis
as described in the instruction manual.
In classification trees established by univariate
split selection, the data are split into two nodes, using
one rule at a time in the form of a question. The splitting
decisions in this case were based on the normalized in-
tensity levels of peaks from the SELDI protein expression
profile. Each peak or cluster identified from the SELDI
profile is therefore a variable in the classification pro-
cess. The process of splitting is continued until terminal
nodes are reached and further splitting has no gain in
data classification. Multiple classification trees were
generated using this process, and the best-performing
tree was chosen for testing. During the analysis, a
pruning step occurs in which branches are removed and
the cost of the removal is determined to establish a
minimal tree size. This is referred to as a “learning set”.
The decision tree was then subjected to cross validation.
In this step, the data are partitioned such that randomly
selected samples are categorized to ensure that the
decision tree is valid. Cross validation is used if data
are insufficient for a separate test sample. In such cases,
Biomarker grows a maximal tree on the entire learning
sample. This is the tree that will be pruned. Biomarker
then proceeds by dividing the learning sample into 10
roughly equal parts, each containing a similar distri-
bution for the dependent variable. Biomarker takes
the first nine parts of the data, constructs the largest
possible tree, and uses the remaining tenth of the data
to obtain initial estimates of the error rate of selected
sub-trees. The same process is then repeated (growing
the largest possible tree) on another 9/10 of the data
while using a different tenth part as the test sample. The
process continues until each part of the data has been
held in reserve one time as a test sample. The results of
the 10 mini-test samples are then combined to form
error rates for trees of each possible size; these error
rates are applied to the tree based on the entire learning
sample. The upshot of this complex process is a set of
fairly reliable estimates of the independent predictive
accuracy of the tree. This allows determination of
how well any tree will perform on completely fresh
data—even if there is no independent test sample.
Because the conventional methods of assessing tree
accuracy can be wildly optimistic, cross validation is the
method Biomarker normally uses to obtain objective
measures for smaller data sets.
The most common way to run Biomarker is to let
Biomarker try to split each node by looking at one
variable at a time. The second split selection method is
the linear combination split option for ordered predictor
variables. An attempt was made to create another
decision tree by comparing several variables at a time
using linear combination splitting. To illustrate this
point, some artificial data were created using the
equation:
linear combination split Y = AX1 + BX2 + CX3
where X1, X2, and X3 are the predictor variables and
A, B, and C are the corresponding linear discriminant
function coefficients. A score for each patient on the
linear discriminant function would be computed as a
composite of each patient’s measurements on the three
predictor variables, weighted by the respective discri-
minant function coefficients. The predicted classification
of each patient as control or diseased would be made by
simultaneously considering the patient’s scores on the
three predictor variables.
Statistical analysis
Specificity was calculated as the ratio of the number of
negative samples correctly classified to the total number
of true negative samples. Sensitivity was calculated as
the ratio of the number of correctly classified diseased
samples to the total number of diseased samples. Com-
parison of relative peak intensity levels between groups
was calculated using Student’s t test.
Results
SELDI protein spectra
The reproducibility of SELDI spectra, i.e. mass location
and intensity between chips, was determined using the
pooled normal plasma quality control sample. Five
protein peaks in the range of 2,000–30,000 Da were
randomly selected over the course of the study and
were used to calculate the coefficient of variance. The
coefficients of variance for peak location and normalized
intensity were 0.05% and 15%, respectively. Plasma
spectra from patients and control women do not show
large variations (Figure 1). Therefore, small variations
between different sample groups could be used for
biomarker discovery. SELDI-TOF mass spectra of plasma
samples were generated. Figure 1 shows that a major
peak with Mr of 8,780.48 Da was consistently lost
in plasma of women with ovarian cancers and a peak
with Mr of 11,537.7 Da was consistently gained in such
plasma.
Establishment of a diagnostic decision tree
Peak labeling was performed with the Biomarker
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Wizard in the Ciphergen ProteinChip software 5.0. Peak
intensities were then transferred to Biomarker Pattern’s
software to establish a decision tree that could most
correctly classify the samples. Statistically significant
peaks within the Mr range 2,000–30,000 Da were used
to generate the classification model. Figure 2 shows
the tree structure of the classification model using the
univariate split selection strategy and sample distri-
butions in analysis of SAX2 chip protein profiles. Three
peaks, with Mr of 8,780.48, 11,537.7 and 5,147.06 Da,
were the best determinants of the decision tree. At
Node 1 (defined by peak 8,780.48), 25 controls and
one cancer patient with peak intensities higher than
18.986 were classified into Terminal Node 1. The other
39 samples were further classified at Node 2 (defined by
peak 11,537.7), where eight controls and two cancer
patients with peak intensity of 0.626 or less were clas-
sified to Terminal Node 2. The other 29 samples entered
Figure 1. Representative differential surface-enhanced laser desorption/ionization time-of-flight mass spectra of ovarian cancer
plasma. Gel (upper panel) and spectral (lower panel) view of plasma protein spectra in low (A) and high (B) molecular weight
range of representative cases, where spectra 1, 2, and 3 were from control women and spectra 4, 5, and 6 were from ovarian cancer
patients. In (A), a protein peak of Mr 8,780.48 Da is present in control plasma but not in ovarian cancer plasma, and in (B), a
protein peak of Mr 11,537.7 Da is present in ovarian cancer plasma but not in control plasma.
  B  A
Node 1
Class = CON
8780.48 ) 18.986
Class Cases
CON 35
T 30
N = 65
Node 2
Class = T
11537.7 ) 0.626
Class Cases
CON 10
T 29
N = 39
Terminal Node 1
Class = CON
Class Cases
CON 25
T 1
N = 26
Terminal Node 2
Class = CON
Class Cases
CON 8
T 2
N = 10
Node 3
Class = T
5147.06 ) 0.251
Class Cases
CON 2
T 27
N = 29
Terminal Node 3
Class = CON
Class Cases
CON 2
T 0
N = 2
Terminal Node 4
Class = CON
Class Cases
CON 0
T 27
N = 27
Figure 2. The decision tree and the distribution of samples in strong anion exchange-2 chip/surface-enhanced laser desorption/
ionization (SELDI) analysis by univariate split. A tree structure of the classification model was generated to best classify the tumor
(T) and control (CON) samples. In the open rectangles, the presence or absence of three SELDI-time-of-flight mass spectrometry
peaks, with Mr of 8,780.48, 11,537.7, and 5,147.06 Da (with thresholds shown following the Mr), serves as root nodes to classify
samples in a hierarchical way. Samples were classified into a lower level root node until the most correct classification was achieved
in the terminal nodes (gray rectangles).
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Node 3 (defined by peak 5,174.06), where two controls
with peak intensities of 0.251 or less went to Terminal
Node 3. The remaining 27 samples, which were all
from cancer patients, were classified to Terminal Node
4. Overall, from the 65 samples, the model correctly
classified all 35 controls and 27 of the 30 cancers,
reaching a sensitivity of 90% and specificity of 100%
in the learning set. Because there was no independent
test sample, the cross-validation method was used to
evaluate the decision tree, which gave a sensitivity of
84% and specificity of 89%.
The second split selection method was the linear
combination split option for ordered predictor variables.
Software analysis generated a linear combination
equation:
–0.0944 (Mr 8,230.48) + 0.0901 (Mr 8,780.48) –
0.991 (Mr 11,537.7) = –0.177
where Mr 8,230.48, 8,780.482, and 11,537.7 Da are
the best determinants. Figure 3 shows the decision tree
distributions generated from the linear combination
method. Among the 65 samples from which SELDI-
TOF spectra were successfully generated, the model
was able to discriminate 33 of the 35 controls and 29
of the 30 cancers, and reached a sensitivity of 97%
and specificity of 94%. Cross validation of this classifi-
cation tree gave a sensitivity of 84% and specificity of
89%.
Discussion
There is broad agreement that analysis of the human
serum proteome has great potential for diagnosis and
early detection of human disease. The challenges are
immense given the complexity of the human proteome
and the broad dynamic range and abundance of in-
dividual proteins. The key to unlocking this potential is
the development of reproducible, sensitive, and specific
technology for proteomic analysis. Recent advances in
technology suggest that this may now be feasible. TOF
MS technology offers a powerful and sensitive tool
to study protein profiles in serum or plasma obtained
from cancer patients and normal subjects. More recently,
there has been considerable interest in analyzing the
SELDI-MS spectral “proteomic pattern” [12–30]. The
high dimensional array, created by the spectrum of
thousands of peptides and their intensities, provides
discriminatory power for separating any given set of
case and control specimens. Although the limitations
of SELDI-MS study design and its analysis have been
discussed in some detail in the literature [16], the
potential implications of such proteomic spectrum
analysis for the identification of novel tumor markers
is huge. It is possible that, in the future, the early detec-
tion of cancers will involve high-throughput proteomic
profiling either alone or in combination with markers
already in use. Validation of the methodology requires
demonstration that the discriminatory algorithm is
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0.0901 (M8,780.48) –
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Figure 3. The decision tree and the distribution of samples in strong anion exchange-2 chip/surface-enhanced laser desorption/
ionization (SELDI) analysis by linear combination split. A tree structure of the classification model was generated to best classify
the tumor (T) and control (CON) samples. In the open rectangles, the presence or absence of five SELDI-time-of-flight mass
spectrometry peaks, with Mr of 8,230.48, 8,780.482, 11,537.7, 13,774.8 and 5,147.065 Da (with thresholds shown following
the Mr), serves as root nodes to classify samples in a hierarchical way. Samples were classified into a lower level root node until
the most correct classification was achieved in the terminal nodes (gray rectangles).
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reproducible among different laboratories and different
sets of case–control specimens. This study demonstrates
the feasibility of detecting protein signatures from cancer
plasma using SELDI-MS and artificial intelligence.
Although additional study is necessary to validate these
patterns as unique diagnostic tools, these proteins are
potentially useful in the diagnosis or monitoring of
ovarian cancer, and, in an easier format, for antibody-
based chip SELDI-TOF technology.
Using protein-chip technology, many studies have
isolated several distinctive protein peaks in ovarian
cancer serum/plasma. One of these has been further
characterized and determined to be haptoglobin-
_1 [7]. In our data, one peak (Mr 11,537.7 Da) was
upreguated in cancer patients. This peak might be
haptoglobin-_1 and, therefore, potentially a useful
biomarker in the detection and monitoring of ovarian
cancer. In order to get a suitable classification model
to discriminate normal and tumor protein profiles,
many statistical methods were applied to test the SELDI
data profile. Appropriate baseline correction and peak
intensity normalization is very important for SELDI data
analysis [15,16]. In comparison with other reports [7,
12,31,32], these data showed high reproducibility,
specificity, and sensitivity.
Recently, important concerns were raised on the
validity of serum proteomic pattern analysis by mass
spectrometry for early cancer diagnosis. First, there are
uncertainties about whether or not it will be possible
to identify subtle changes caused by early ovarian cancer
in a low-abundance protein or protein fragment.
Diamandis argues that this approach would identify
high-abundance proteins in the circulation that are not
released by the tumor, likely representing nonspecific
epiphenomena of cancer [16]. If so, it may prove diffi-
cult to achieve adequate sensitivity for early detection
of preclinical ovarian cancer using current technology.
Second, there are many potential variables and con-
sequently possible sources of bias related to differ-
ences between cases and controls, as well as variations
in sample collection, processing, and storage. For
example, in the Petricoin et al report, there was a 10-
year difference in the mean age of the control group and
the ovarian cancer group, so the differences observed
could have been related to factors such as age or meno-
pausal status [12]. Several of these points highlight the
need for careful selection of samples in future proteo-
mic studies. It is essential that studies utilize samples
from carefully matched populations collected and stored
under the same conditions.
In conclusion, up to now, SELDI-TOF MS is not sen-
sitive enough to identify molecules in the subnanogram
per milliliter range. It remains to be seen whether
further refinements, such as fractionation enrichment
techniques, will yield clinically useful diagnostic meth-
ods for cancer. Therefore, it seems desirable to know
the identity of the biomarkers in the pattern in order to
understand their significance in disease pathogene-
sis, as has been reported with the use of SELDI-MS to
identify amyloid-`-peptide as a diagnostic marker for
Alzheimer’s disease [33–35] and _-defensin 1, 2, 3 as a
favorable prognostic marker in acquired immune
deficiency and contributor to anti-HIV-1 activity [36].
We hope in the future to identify these protein peaks
and combine them with other markers such as CA125 or
CA15-3 to assess therapeutic response and increase
early detection of relapse of ovarian cancer.
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